Navigation Links
KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Prevent and Reverse Atherosclerotic Heart Disease

EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, announced today the first method for measuring the efflux of cholesterol from tissues in animals through the pathway known as reverse cholesterol transport (RCT). RCT is the only known mechanism by which excess cholesterol can be removed from tissues and has therefore received considerable attention as a therapeutic target for prevention and reversal of atherosclerosis. The data, presented at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Meeting in Chicago, compared the effects of several therapeutic approaches on RCT in real-time, in living animals. KineMed also presented data from its researchers and their collaborators at the University of California, Berkeley and the University of California, San Francisco demonstrating that KineMed's technology successfully measured levels of efflux of cholesterol from the tissues in human subjects.

    The data were presented in posters titled,

    --  "Measurement of Cholesterol Efflux and Global Reverse Cholesterol

        Transport Rates in Vivo with Stable Isotopes", which described in

        detail the proprietary method for measuring the flow of cholesterol

        molecules out of tissues into the bloodstream and then from the

        bloodstream out of the body, and

    --  "Effect of Reconstituted HDL on Cholesterol Efflux from Tissues in

        Vivo".  This poster showed that infusion of CSL-111 (provided by CSL

        Behring AG), which is reconstituted high density lipoprotein (rHDL)

        particles, into animals increased efflux of cholesterol

        out of tissues into the bloodstream.

In addition, data were presented in an invited plenary session talk by Marc Hellerstein M.D., Ph. D., Co-founder and Chief of the Scientific Advisory Board of KineMed, as well as Professor (Calloway Chair of Human Nutrition), University of California, Berkeley, and Professor of Medicine, University of California, San Francisco. The talk was titled,

    -- "Measuring Reverse Cholesterol Transport and Insulin-Mediated Glucose

       Utilization In Vivo in Animal Models and Humans: Pathway Fluxes as

       Therapeutic Targets". This presentation reviewed the role of

       critical pathways, including RCT, in drug discovery and development.

Dr. Hellerstein stated, "The importance of measuring changes in RCT in the intact animal or patient is highlighted by recent clinical failures in the HDL/atherosclerosis field, which have left a therapeutic void. KineMed's technology can become an integral part of efforts to discover and develop promising agents that treat and reverse atherosclerosis, thereby positioning KineMed as a leader in this field."

RCT is one of the many pathways for which KineMed has the unique technology and IP to measure in intact animals and patients. The RCT technology is currently being used by KineMed and its Pharma partners in preclinical studies as a target for screening candidate compounds, validating target activity, selecting among leads, and optimizing treatment regimes. The Company is also working with Pharma partners in clinical trials to rapidly demonstrate on-mechanism therapeutic effect in patients.

About KineMed, Inc.

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of infl ammation and neurodegeneration.

KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.

For further information about KineMed, please visit:

CONTACT: Brent Vaughan, Chief Business Officer of KineMed, Inc.,+1-510-655-6525, ext. 110, or media, Justin Jackson of Burns McClellan,+1-212-213-0006, or , for KineMed, Inc.

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Regardless of ... environments, corporate communications is perpetually evolving. Due to ... professionals must continuously adjust their business-to-business (B2B) communication ... adjustments is difficult, but also critical as a ... --> --> ...
(Date:10/9/2015)... 2015  Insulet Corporation (NASDAQ: PODD ), the ... its OmniPod ® Insulin Management System, today announced ... quarter of 2015 on November 5, 2015 after the ... release, management will host a conference call that day ... . A replay will be available two hours after ...
(Date:10/9/2015)... Maryland , October 9, 2015 ... Inc. (OTCQB: CNBX) has announced its execution of an Intellectual ... & Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related ... company. --> --> ... restructuring of the Company, whereby the Research and Development ...
Breaking Medicine Technology:
... 2010 Decision Resources, one of the world,s leading research ... by 2019 the acute gout drug market will triple in ... will reach $1.83 billion. According to the ... Agents Target Refractory Patients and Tap Market Opportunity, both ...
... Physiotherapy Associates, the nation,s foremost provider of outpatient ... includes physical therapy services and a health and wellness ... MS for patients, available in its more than 600 ... MS Specialty Program will benefit the more than 400,000 ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify if ... online ( ) – just in time for the cold and flu season, ... However, for many in the U.S., the real start of cold/flu season is the ...
Breaking Medicine News(10 mins):
... ... medical journal Osteoporosis International found that women taking AdvaCAL® calcium had the highest bone ... 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and 7 different types of ... ...
... ... Dermatologist settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this ... Rattan was presented at a ceremony in connection with the yearly International ... Heavy Industries and Public Enterprises, Government of India. Dr. Mehta was awarded ...
... ... IL based management consulting and technology firm, today announced it will merge ... Gold Certified Partner, effective January 1, 2010. Logan Consulting is ... America, Europe and Asia since 1992. Under the new structure, ...
... , ... Omnetics Connector Corporation, the leading manufacturer of miniature high-rel connectors, is utilizing their ... , ... MN (Vocus) January 29, 2010 -- Omnetics Connector Corporation, the leading manufacturer of ...
... ... Vemma Nutrition Company launches Vemma ... or other sports drinks, Vemma THIRST goes beyond hydration by ... minerals, while replenishing the body with necessary electrolytes, specialized carbohydrates ...
... , , Majority of Mississippi ... Jan. 28 The following is a statement by ... Consumer Healthcare Products Association (CHPA): , "Today, the Mississippi ... that, if it becomes law, will greatly limit how cold and ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: